CSL Seqirus’ mRNA COVID vaccine for the prevention of COVID 19 is filed by Meiji Holdings in Japan.
Meiji Holdings announced on April 28 that subsidiary Meiji Seika Pharma has filed an application seeking Japanese regulatory approval for ARCT -154, an mRNA vaccine in-licensed from CSL Seqirus, for a primary two-dose inoculation for the prevention of COVID-19 in adults
The submission comes after Meiji Pharma announced the signing of a deal with CSL Seqirus earlier this month for the distribution and sales of the next-generation mRNA vaccine in Japan. The vaccine was developed by US biotech Arcturus Therapeutics, with the CSL subsidiary holding its exclusive worldwide rights.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.